Published in Medical Letter on the CDC and FDA, March 5th, 2006
According to a report from the United States, "Androgen deprivation therapy is a mainstay for the treatment of advanced prostate cancer. Hormonal therapy commonly consists of injection of gonadotropin hormone-releasing hormone agonists."
"Based on the need for improved convenience of administration, a novel formulation of leuprolide acetate (Ellgard; Atrix Laboratories Inc. and Sanofi Aventis) which incorporates a mixture of selected polymers and solvents to achieve sustained drug delivery after subcutaneous injection, was developed," reported Michael C. Cox and colleagues...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Medical Letter on the CDC and FDA
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.